GlassScriptPhysician profile
Sachin Gupta
NPI 1215163183
$85,732.02
in general payments reported to CMS, 2019-2025
14 companies · $254 in 2025
The $254 reported for 2025 was more than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $71K · 2020: $14K · 2022: $20.63 · 2023: $66.56 · 2024: $258 · 2025: $254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $578.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $578.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $43,188.46 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $24,603.06 | 2019 | |
| Insmed, INC. | $8,407.63 | 2019 | |
| United Therapeutics Corporation | $5,979.08 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $3,068.67 | 2019 | |
| Merck Sharp & Dohme LLC | $176.88 | 2019-2024 | Winrevair |
| Novartis Pharmaceuticals Corporation | $94.15 | 2023-2024 | |
| Accord Healthcare, INC. | $56.70 | 2025 | |
| Avyxa Pharma, LLC | $54.05 | 2025 | |
| Alnylam Pharmaceuticals INC. | $24.51 | 2023 | Onpattro |
| Janssen Pharmaceuticals, INC | $23.75 | 2019 | |
| Glaxosmithkline, LLC. | $18.62 | 2019 | |
| Circassia INC. | $18.25 | 2019 | |
| Mylan Specialty L.P. | $18.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sachin Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.